RxDoctor Payments Data

Bolaji Sofola, MD

Urology · Ardmore, OKNPI 1366406217

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,230 of the $10,612 with a category attached, or 87.0%. It is spread thinly across 45 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations.

$10,612in general payments, 2019–2025

Across 456 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Procept Biorobotics Corporation$1K
  • Bayer$795
  • Medtronic$785
  • Myriad Genetic Laboratories, Inc.$736
  • Coloplast$528
  • plus $5K from 39 others

What the payments were for

  • Travel & lodging$8008%
  • Food & beverage$9,23087%
  • Education$5825%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,612 in reported general payments places this provider in the 80th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$658,667
Medicare patients
801
Services billed
15,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron275$162,734
GemtesaVibegron88$53,101
Tamsulosin Hcl630$11,329
Dutasteride324$8,577
NitrofurantoinNitrofurantoin Macrocrystal103$8,505
JatenzoTestosterone Undecanoate12$5,945
Testosterone40$5,523
Potassium Citrate ErPotassium Citrate116$5,177
Solifenacin Succinate41$4,570
Testosterone Cypionate84$3,932
Oxybutynin Chloride ErOxybutynin Chloride203$3,534
Estradiol52$3,510
Tadalafil33$3,437
Bethanechol Chloride73$2,461
Doxycycline Hyclate107$1,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,449$162,734275 claims
Sumitomo Pharma America, Inc.Gemtesa$525$53,10188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 145 urology providers in Oklahoma.

Other urology in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →